172 related articles for article (PubMed ID: 15693139)
1. In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells.
Dall P; Herrmann I; Durst B; Stoff-Khalili MA; Bauerschmitz G; Hanstein B; Niederacher D
Cancer Immunol Immunother; 2005 Jan; 54(1):51-60. PubMed ID: 15693139
[TBL] [Abstract][Full Text] [Related]
2. Efficient lysis of CD44v7/8-presenting target cells by genetically engineered cytotoxic T-lymphocytes--a model for immunogene therapy of cervical cancer.
Dall P; Hekele A; Beckmann MW; Bender HG; Herrlich P; Ponta H
Gynecol Oncol; 1997 Aug; 66(2):209-16. PubMed ID: 9264564
[TBL] [Abstract][Full Text] [Related]
3. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.
Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
J Immunol; 2002 Nov; 169(10):5780-6. PubMed ID: 12421958
[TBL] [Abstract][Full Text] [Related]
4. Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera.
Hekele A; Dall P; Moritz D; Wels W; Groner B; Herrlich P; Ponta H
Int J Cancer; 1996 Oct; 68(2):232-8. PubMed ID: 8900434
[TBL] [Abstract][Full Text] [Related]
5. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
Blood; 2002 Nov; 100(9):3155-63. PubMed ID: 12384413
[TBL] [Abstract][Full Text] [Related]
6. Melanoma Immunotherapy in Mice Using Genetically Engineered Pluripotent Stem Cells.
Haque M; Song J; Fino K; Sandhu P; Wang Y; Ni B; Fang D; Song J
Cell Transplant; 2016; 25(5):811-27. PubMed ID: 26777320
[TBL] [Abstract][Full Text] [Related]
7. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity.
Moritz D; Groner B
Gene Ther; 1995 Oct; 2(8):539-46. PubMed ID: 8593604
[TBL] [Abstract][Full Text] [Related]
8. Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells.
Morgenroth A; Cartellieri M; Schmitz M; Günes S; Weigle B; Bachmann M; Abken H; Rieber EP; Temme A
Prostate; 2007 Jul; 67(10):1121-31. PubMed ID: 17492652
[TBL] [Abstract][Full Text] [Related]
9. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma.
Haynes NM; Snook MB; Trapani JA; Cerruti L; Jane SM; Smyth MJ; Darcy PK
J Immunol; 2001 Jan; 166(1):182-7. PubMed ID: 11123291
[TBL] [Abstract][Full Text] [Related]
10. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
[TBL] [Abstract][Full Text] [Related]
11. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
[TBL] [Abstract][Full Text] [Related]
12. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.
Altenschmidt U; Klundt E; Groner B
J Immunol; 1997 Dec; 159(11):5509-15. PubMed ID: 9548491
[TBL] [Abstract][Full Text] [Related]
13. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.
Rossig C; Bär A; Pscherer S; Altvater B; Pule M; Rooney CM; Brenner MK; Jürgens H; Vormoor J
J Immunother; 2006; 29(1):21-31. PubMed ID: 16365597
[TBL] [Abstract][Full Text] [Related]
14. Tumor vessel-injuring ability improves antitumor effect of cytotoxic T lymphocytes in adoptive immunotherapy.
Kanagawa N; Yanagawa T; Nakagawa T; Okada N; Nakagawa S
Cancer Gene Ther; 2013 Jan; 20(1):57-64. PubMed ID: 23175243
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic carcinoma-specific immunotherapy using novel tumor specific cytotoxic T cells.
Lei J; Wu Z; Jiang Z; Li J; Zong L; Chen X; Duan W; Xu Q; Zhang L; Han L; Ma Q; Wang Z; Zhang D
Oncotarget; 2016 Dec; 7(50):83601-83610. PubMed ID: 27876704
[TBL] [Abstract][Full Text] [Related]
16. Specific cytotoxic T lymphocytes in gene therapy.
Altenschmidt U; Moritz D; Groner B
J Mol Med (Berl); 1997 Apr; 75(4):259-66. PubMed ID: 9151212
[TBL] [Abstract][Full Text] [Related]
17. Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy.
Cheung NK; Guo HF; Modak S; Cheung IY
Hybrid Hybridomics; 2003 Aug; 22(4):209-18. PubMed ID: 14511566
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells.
Moritz D; Wels W; Mattern J; Groner B
Proc Natl Acad Sci U S A; 1994 May; 91(10):4318-22. PubMed ID: 7910405
[TBL] [Abstract][Full Text] [Related]
19. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
[TBL] [Abstract][Full Text] [Related]
20. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
